{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T23:55:54Z","timestamp":1767830154695,"version":"3.49.0"},"reference-count":41,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T00:00:00Z","timestamp":1641513600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005297","name":"Medical University of Bia\u0142ystok","doi-asserted-by":"publisher","award":["SUB\/1\/DN\/19\/001\/1149"],"award-info":[{"award-number":["SUB\/1\/DN\/19\/001\/1149"]}],"id":[{"id":"10.13039\/501100005297","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biology"],"abstract":"<jats:p>Galectin-3 (gal-3) is a multifunctional regulator of various biological processes and diseases, which are common comorbidities in psoriasis. Data regarding potential diagnostic role of gal-3 in psoriasis are insufficient. Serum gal-3 levels were evaluated before and after twelve weeks of treatment with acitretin or methotrexate in 31 patients with plaque-type psoriasis and compared to 11 healthy control group. The mean serum galectin-3 level in patients with psoriasis was significantly higher compared to the control group (p &lt; 0.01). In patients with obesity and long-lasting psoriasis (&gt;20 years) positive relations of gal-3 and PASI were noted. In psoriatics with low gal-3 levels, positive correlations between the gal-3 and BMI, glucose level, and with the latter in short-lasting psoriasis (&lt;20 years) were noted. In the long history of psoriasis, gal-3 was negatively correlated with lipids levels. The Gal-3 level might be a multifaceted modulator of the course of psoriasis and predictive factor of cardiometabolic comorbidities\u2019 development, especially in patients with a long history of the disease or obesity. Patients with low serum gal-3 and short history of psoriasis are presumably at greater risk of diabetes. In patients with long-lasting psoriasis and concomitant obesity, gal-3 may exert a protective role against dyslipidemia or perhaps further CMD development.<\/jats:p>","DOI":"10.3390\/biology11010088","type":"journal-article","created":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T03:46:27Z","timestamp":1641527187000},"page":"88","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Galectin-3 as a Novel Multifaceted and Not Only Cardiovascular Biomarker in Patients with Psoriasis with Regard to Systemic Treatment\u2014Preliminary Data"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8018-9960","authenticated-orcid":false,"given":"Anna","family":"Baran","sequence":"first","affiliation":[{"name":"Department of Dermatology and Venereology, Medical University of Bialystok, Zurawia 14 St., 15-540 Bialystok, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulina","family":"Kiluk","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, Medical University of Bialystok, Zurawia 14 St., 15-540 Bialystok, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6870-1167","authenticated-orcid":false,"given":"Julia","family":"Nowowiejska","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, Medical University of Bialystok, Zurawia 14 St., 15-540 Bialystok, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8688-4171","authenticated-orcid":false,"given":"Tomasz W.","family":"Kaminski","sequence":"additional","affiliation":[{"name":"Pittsburgh Heart, Lung and Blood Vascular Medicine Institute, University of Pittsburgh, Pittsburgh, PA 15260, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Maciaszek","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Hepatology, Medical University of Bialystok, Zurawia 14 St., 15-540 Bialystok, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iwona","family":"Flisiak","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, Medical University of Bialystok, Zurawia 14 St., 15-540 Bialystok, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,1,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/jdv.13854","article-title":"A systematic review od worldwide epidemiology of psoriasis","volume":"31","author":"Michalek","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Kanda, N. (2021). Psoriasis: Pathogenesis, Comorbidities, and Therapy Updated. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22062979"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"345","DOI":"10.4082\/kjfm.20.0053","article-title":"Psoriasis and Cardiovascular Disease: A Narrative Review","volume":"42","year":"2021","journal-title":"Korean J. Fam. Med."},{"key":"ref_4","first-page":"9","article-title":"Psoriasis: Comorbidities and associations","volume":"146","author":"Farley","year":"2011","journal-title":"G Ital. Dermatol. Veneorol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Nowowiejska, J., Baran, A., and Flisiak, I. (2021). Aberrations in lipids Aberrations in Lipid Expression and Metabolism in Psoriasis. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22126561"},{"key":"ref_6","first-page":"128","article-title":"Psoriasis, metabolic syndrome and cardiovascular risk factors. A population-based study","volume":"33","author":"Gari","year":"2018","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.jaad.2018.12.037","article-title":"All-cause and cause-specific mortality in psoriasis: A systematic review and meta-analysis","volume":"80","author":"Dhana","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"775.e1","DOI":"10.1016\/j.amjmed.2011.03.028","article-title":"Attributable Risk Estimate of Severe Psoriasis on Major Cardiovascular Events","volume":"124","author":"Mehta","year":"2011","journal-title":"Am. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Baran, A., Nowowiejska, J., Krahel, J.A., Kaminski, T.W., Maciaszek, M., and Flisiak, I. (2020). Higher Serum Selenoprotein P Level as a Novel Inductor of Metabolic Complications in Psoriasis. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21134594"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Krahel, J.A., Baran, A., Kaminski, T.W., Maciaszek, M., and Flisiak, I. (2020). Methotrexate Decreases the Level of PCSK9-A Novel Indicator of the Risk of Proatherogenic Lipid Profile in Psoriasis. The Preliminary Data. J. Clin. Med., 9.","DOI":"10.3390\/jcm9040910"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Dings, R.P.M., Miller, M.C., Griffin, R.J., and Mayo, K.H. (2018). Galectins as Molecular Targets for Therapeutic Intervention. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19030905"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2018\/9186940","article-title":"The Role of Galectins as Modulators of Metabolism and Inflammation","volume":"2018","author":"Brinchmann","year":"2018","journal-title":"Mediat. Inflamm."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Sciacchitano, S., Lavra, L., Morgante, A., Ulivieri, A., Magi, F., De Francesco, G.P., Bellotti, C., Salehi, L.B., and Ricci, A. (2018). Galectin-3: One Molecule for an Alphabet of Diseases, from A to Z. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19020379"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Hara, A., Niwa, M., Noguchi, K., Kanayama, T., Niwa, A., Matsuo, M., Hatano, Y., and Tomita, H. (2020). Galectin-3 as a Next-Generation Biomarker for Detecting Early Stage of Various Diseases. Biomolecules, 10.","DOI":"10.3390\/biom10030389"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jdermsci.2011.07.008","article-title":"Galectin-3 and the skin","volume":"64","author":"Larsen","year":"2011","journal-title":"J. Dermatol. Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1590\/abd1806-4841.20198426","article-title":"Galectin 3: An extraordinary multifunctional protein in dermatology. Current knowledge and perspectives","volume":"94","author":"Pasmatzi","year":"2019","journal-title":"An. Bras. de Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"50","DOI":"10.5114\/dr.2017.66222","article-title":"Significance of selected inflammatory factors in metabolic disorders in association with psoriasis","volume":"1","author":"Kiluk","year":"2017","journal-title":"Dermatol. Rev."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Blair, B.B., Funkhouser, A.T., Goodwin, J.L., Strigenz, A.M., Chaballout, B.H., Martin, J.C., Arthur, C.M., Funk, C.R., Edenfield, W.J., and Blenda, A.V. (2021). Increased Circulating Levels of Galectin Proteins in Patients with Breast, Colon, and Lung Cancer. Cancers, 13.","DOI":"10.3390\/cancers13194819"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e130740","DOI":"10.1172\/JCI130740","article-title":"Galectin-7 downregulation in lesional keratinocytes contributes to enhanced IL-17A signaling and skin pathology in psoriasis","volume":"131","author":"Chen","year":"2021","journal-title":"J. Clin. Investig."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2020\/5284728","article-title":"Galectin-3 Is a Potential Mediator for Atherosclerosis","volume":"2020","author":"Gao","year":"2020","journal-title":"J. Immunol. Res."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Blanda, V., Bracale, U.M., Di Taranto, M.D., and Fortunato, G. (2020). Galectin-3 in Cardiovascular Diseases. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21239232"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/nrcardio.2010.51","article-title":"Early detection of myocardial dysfunction and heart failure","volume":"7","author":"Ouzounian","year":"2010","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s40256-019-00387-9","article-title":"Value of Galectin-3 in Acute Myocardial Infarction","volume":"20","author":"Li","year":"2019","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1093\/eurjhf\/hft077","article-title":"Galectin-3 in heart failure with preserved ejection fraction","volume":"15","author":"Edelmann","year":"2013","journal-title":"Eur. J. Hear. Fail."},{"key":"ref_25","first-page":"000785","article-title":"Galectin-3, a Biomarker Linking Oxidative Stress and Inflammation With the Clinical Outcomes of Patients With Atherothrombosis","volume":"3","author":"Lindholt","year":"2014","journal-title":"J. Am. Hear. Assoc."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Ram\u00edrez-Ter\u00e1n, A.L., Vega-Memije, M.E., Torres-Tamayo, M., and Mart\u00ednez-Alvarado, M.R. (2021). Carotid intima-media thickness in patients with psoriasis with and without metabolic syndrome. Arch. Cardiol. Mex.","DOI":"10.24875\/ACME.M22000339"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/jdv.15211","article-title":"Role of galectin-3 in subclinical myocardial impairment in psoriasis","volume":"33","author":"Kotwica","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_28","first-page":"10","article-title":"Glycophenotype of psoriatic skin","volume":"52","author":"Lacina","year":"2006","journal-title":"Folia Biol. (Praha)"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1600-0625.1994.tb00260.x","article-title":"Expression of epsilon BP, a bet-galactoside-binding soluble lectin, in normal and neoplastic epidermis","volume":"3","author":"Konstantinov","year":"1994","journal-title":"Exp. Dermatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1002\/ijc.22848","article-title":"Inhibition of Wnt-2 and galectin-3 synergistically destabilizes beta-catenin and induces apoptosis in human colorectal cancer cells","volume":"121","author":"Shi","year":"2007","journal-title":"Int. J. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jaut.2017.11.002","article-title":"Decrease of galectin-3 in keratinocytes: A potential diagnostic marker and a critical contributor to the pathogenesis of psoriasis","volume":"89","author":"Shi","year":"2018","journal-title":"J. Autoimmun."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e000026","DOI":"10.1136\/lupus-2014-000026","article-title":"Plasma levels of galectin-3-binding protein reflect type I interferon activity and are increased in patients with systemic lupus erythematosus","volume":"1","author":"Nielsen","year":"2014","journal-title":"Lupus Sci. Med."},{"key":"ref_33","first-page":"41","article-title":"Serum galectin-3 and galectin-3 binding protein levels in Beh\u00e7et\u2019s disease and their association with disease activity","volume":"25","author":"Lee","year":"2007","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"650605","DOI":"10.3389\/fphar.2021.650605","article-title":"Circulating Galectin-1 and Galectin-3 in Sera From Patients With Systemic Sclerosis: Associations With Clinical Features and Treatment","volume":"12","author":"Sundblad","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e14545","DOI":"10.1111\/ijcp.14545","article-title":"Serum galectin-3 levels in patients with psoriasis","volume":"75","author":"Hayran","year":"2021","journal-title":"Int. J. Clin. Pract."},{"key":"ref_36","first-page":"152","article-title":"Correlation Between Serum Galectin-3 Levels and Disease Severity in Psoriasis Vulgaris","volume":"45","author":"Ozden","year":"2011","journal-title":"T\u00fcrk. Derm."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s40618-014-0222-2","article-title":"Increased levels of galectin-3 were associated with prediabetes and diabetes: New risk factor?","volume":"38","author":"Yilmaz","year":"2015","journal-title":"J. Endocrinol. Investig."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.3760\/cmaj.issn.0366-6999.20130217","article-title":"Serum galectin-3: A risk factor for vascular complications in type 2 diabetes mellitus","volume":"126","author":"Jin","year":"2013","journal-title":"Chin. Med. J."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1093\/eurheartj\/ehs077","article-title":"Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA)","volume":"33","author":"Gullestad","year":"2012","journal-title":"Eur. Hear. J."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/apt.13816","article-title":"Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis","volume":"44","author":"Harrison","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.jaad.2017.05.055","article-title":"A phase 2a, open-label pilot study of the galectin-3 inhibitor GR-MD-02 for the treatment of moderate-to-severe plaque psoriasis","volume":"77","author":"Ritchie","year":"2017","journal-title":"J. Am. Acad. Dermatol."}],"container-title":["Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-7737\/11\/1\/88\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T14:00:38Z","timestamp":1760364038000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-7737\/11\/1\/88"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,7]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1]]}},"alternative-id":["biology11010088"],"URL":"https:\/\/doi.org\/10.3390\/biology11010088","relation":{},"ISSN":["2079-7737"],"issn-type":[{"value":"2079-7737","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,7]]}}}